Searched for
DILIP SHANGHVI AND ASSOCIATES
Ram Shriram's Sherpalo Ventures to lead $60 million funding round in Skyroot; valuation hits $1.1 billionGIC, of Singapore, BlackRock, Greenko Group founders take part in round along with Sun Pharma founder Dilip Shanghvi family office as the 9...- Suzlon Energy shares fall over 3% after Dilip Shanghvi and Associates terminate 2020 pactShares of Suzlon Energy fell 3% to Rs 25 in Wednesday's trade on BSE after the Sun Pharma promoter Dilip Shanghvi and Associates decided to...
- Dilip Shanghvi & Associates terminate 2020 pact with Suzlon EnergyWith the termination of the agreement, the investor group's nominee director on Suzlon's board, Hiten Timbadia, has also resigned with effe...
- Dilip Shanghvi resigns as MD of SPARCIt further stated that the board, on the recommendation of Nomination and Remuneration Committee, has appointed Anil Raghavan as chief exec...
- Sun Pharma promoters take a hit on personal investmentsSome of their biggest personal investments have been in power and real estate, and both sectors and their holdings have taken a beating, ac...
- Jaypee Infra lenders reject Lakshadweep’s proposalETon May 3 reported that the committee was set to reject the offer from Lakshadweep, a venture promoted by some relatives of pharma billion...
- Dilip Shanghvi, IDFC Bank, Telenor drop plans to set up payments bankThe decision to abandon plans to set up a payments bank was taken as the promoters felt that they lacked adequate physical presence in term...
- Open offer to acquire 26 per cent stake in Suzlon draws poor responseUnder the open offer, Shanghvi and associates had to acquire 26 per cent stake for Rs 2,837 crore in the wind turbine maker.
- Uninor rebrands itself Telenor, to spend Rs 100 crore on marketing new nameTelenor India will continue to position itself as the 'sabse sastaa' or the lowest costing voice and data services provider in the country.
- Competition Commission approves Dilip Shanghvi's proposed Rs 1,800-crore deal with SuzlonThe deal, announced in February this year, would see Shanghvi acquiring at least 23 per cent stake in Suzlon which has been grappling with ...
- Dilip Shanghvi in talks for a stake buy in ABG ShipyardTroubled shipbuilder ABG Shipyard is looking for a white knight and it's now pinning hopes on India's richest man Dlilip Shanghvi for a bai...
- Suzlon Energy rallies nearly 20% on Sun Pharma promoter's open offerSuzlon Energy last week signed definitive agreements with Dilip Shanghvi Family and Associates (DSA) for equity investments of Rs 1,800 cro...
- Dilip Shanghvi diversifies to expand his business, makes big investments in power and bankingThis weekend, Shanghvi announced a Rs 1,400-crore investment to pick up 23% stake in ailing renewable energy company Suzlon through DSA.
- Suzlon soars 20% on Dilip Shanghvi deal; adds Rs 1,089 crore to m-capSuzlon today surged nearly 20 per cent, following pacts with Dilip Shanghvi Family and Associates for equity investments of Rs 1,800 crore.
- Dilip Shanghvi, associates make open offer for 26% stake in SuzlonThe open offer price for 157.64 crore shares is Rs 18 per scrip, a total of about Rs 2,837.52 crore.
- Suzlon rallies over 18% as Dilip Shanghvi invests Rs 1800 cr, triggers open offerThe company plans to build wind-power equipment factories as it seeks to recover from India’s biggest convertible-bond default two-and-a-ha...
- Sun Pharma's Dilip Shanghvi to acquire 23% in Suzlon Energy for Rs 1,800 croreSuzlon’s promoters will retain management control “by virtue of pooling arrangement for voting”, while the Shanghvi family will remain a fi...
- Dilip Shanghvi, Sun Pharma promoter, a pharma maven with midas touchHis staff call him India's most aggressive promoter whose calm demeanour shadows his killer instincts when it comes to splurging on riskies...
- Sun Pharma enhances revenue guidance to 25% for Fiscal Year 14The revised guidance takes into account the risks associated with increase in competition for some products. Guidance is at constant exchan...
- Pharmaceutical companies should consider mergers: Dilip ShanghviPharmaceutical companies, who are battling growing competition from each other and resurgent multinationals, may have to shake hands.
Load More
